IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of: Heike STROBEL, et al.

Serial No.: To be assigned

Art Unit: To be assigned

Filing Date: Concurrently Herewith

Examiner: To be assigned

For: REDUCTION OF SPONTANEOUS MUTATION RATES IN CELLS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

LA		and officially made of record in accordance with the provisions of 57 CFR 1.57				
	[]	Copies of the following references are enclosed. Copies of the references were submitted in parent application Serial No (37 CFR 1.98(d)) A copy of the International Search Report which issued on International Application No. PCT/EP2005/002067 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.				
A.	A. [X] The Information Disclosure Statement submitted herewith is being filed within three filing date of the above application or date of entry into the national stage of an inte application or before the mailing date of a first Office action on the merits, whichev occurs last. 37 CFR 1.97(b).					
	OR					
	[]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).				
B.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.				
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.				
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).				

C.	The Information Disclosure Statement transmitted herewith is being filed after a final action of 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.								
	In accordance with the requirements of 37 CFR 1.97(d):								
	[Applicant hereby certifies that each item of information contained in this Information Disclosured Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]							
	[Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information							

[] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

1.56(c) more than three months prior to the filing of this statement; and

- [X] Please charge any required fees to Deposit Account No.07-1392.
- [X] A duplicate copy of this paper is attached.

Respectfully Submitted,

contained in this Information Disclosure Statement was known to any individual designated in §

Frank P. Grassler, Attorney of Record

Registration No. 31,164

Date: August 28, 2006 GlaxoSmithKline Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-2482 Facsimile: (919) 483-5730

10/590829 IAF12 Rec'd PCT/PT028 AUG 2006

C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under §					
		1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the					
		issue fee. Also enclosed is a copy of the International Search Report which Issued on International					
		Publication No.					

In accordance with the requirements of 37 CFR 1.97(d):

- Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- [] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- [] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [X] A duplicate copy of this paper is attached.

Respectfully Submitted,

Frank P. Grassler, Attorney of Record

Registration No. 31,164

Date: August 28, 2006 GlaxoSmithKline Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-2482 Facsimile: (919) 483-5730

IAP12 Rec's PGT/PTO 28 AUG2006

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. O SERIAL TO 829				
					APPLICANT: Heike STROBEL, et al.			
					FILING DATE:		GROUP	
			II.C. P.	· mraim p	Concurrently Herewith To be assigned			
		T	U.S. P.	ATENT D	OCUMENTS	Т	T	
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate
		ļ <u>.</u>	<u> </u>	 		 		
			 	 		 	 	
		 	 	+		 	+	
		 	 	 		 	-	
-			 	†		 	+	
	-				****	1	 	
<u> </u>								
		·		ontinue on p		· · · _		
		Decument		N PATENT	Γ DOCUMENTS	1	7	T
		Document Number	Publication Date		Country	Class	Subclass	Translation Yes No
							1	
<u></u>								
 			 		· ·	<u> </u>	·	-
						 	 	
 			1	-		 	-	
l			 - 			+	1	
L		<u> </u>	Cı	ontinue on p	nage	<u></u>	<u> </u>	<u> </u>
		OTHER DOCUM	MENTS (Includin	ng Author,	Title, Journal-Date, P	age Numb	er. Etc.)	
	1.	OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) Foster, Patricia, et al., "Proofreading-defective DNA polymerase II increases adaptive mutation in Escherichia coli," PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 92, no. 17, 1995, pp. 7951-7955.						S OF
	Zhao, Jingyong, et al., "Reduction of GC fwdarw TA transversion mutation by overexpression of MutS in Escherichia coli K-12," <i>JOURNAL OF BACTERIOLOGY</i> , vol. 182, no. 17, September 2000, pp. 5025-5028						lutS in 025-5028.	
		 						
								
 								
-								
			C	ontinue on	page			
EXAMINER	/Je 	ennifer Graser/				DATE CO	ONSIDERED	11/19/2010
					s in conformance with N			ough citation
if not in confo	rmanc	e and not considere	ed. Include copy of	of this form	with next communicati	on to the ap	plicant.	